Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis allows generic sales in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties.

The agreement settles a three-year US patent infringement suit issued against generic manufacturers Barr Pharmaceuticals and Teva Pharmaceuticals. The agreement states that in exchange for royalties, Barr and Teva can sell cheaper versions of the allergy drugs Allegra and Nasacort in the US. Royalties are to be applied to sales retrospectively.

Under the terms of the agreement, Barr will have an option to purchase the finished pharmaceutical product from sanofi-aventis on a non-exclusive basis.

Sanofi-aventis is continuing with ongoing patent infringements suits against other generic manufacturers.

In 2007, US sales of Allegra and Nasacort totalled $276m and $301m, respectively.

19th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics